Reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 6, 2026
Triptorelin (TRIP) is a sexual health peptide, at the fda approved stage in the published literature. GnRH agonist used medically for prostate cancer and precocious puberty. Can restart HPTA when used appropriately.
GnRH agonist used medically for prostate cancer and precocious puberty. Can restart HPTA when used appropriately.
| Research Status | FDA approved |
|---|---|
| Half-Life | 3-5 hours (depot forms longer) |
| Administration | Intramuscular injection |
| Doses Reported in Published Studies | 100 mcg (single dose for HPTA) |
Initial GnRH receptor stimulation followed by downregulation with continued use.
GnRH agonist used medically for prostate cancer and precocious puberty. Can restart HPTA when used appropriately.
Initial GnRH receptor stimulation followed by downregulation with continued use.
Triptorelin is at the following stage in the published literature: FDA approved. All information is for research and educational purposes only.
Reported half-life: 3-5 hours (depot forms longer).
Reported administration route in the literature: Intramuscular injection. This is not a recommendation for human use.
Educational content, not medical advice. Effects described are drawn from cited research in study subjects.